Value Sense
LBPH
Longboard Pharmaceuticals, Inc. (LBPH)
Last Price$60.00.0%
Market Cap$2,336.7M
LTM Gross margin
50.0%
5Y avg
8.6%
Biotechnology industry median
69.2%
Stock quality & Intrinsic value
6/10
(0.8%) overvalued
LBPH
is (81.3%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Longboard Pharmaceuticals, Inc. Gross margin

Annual
Quarterly
LTM
Industry median
Company stand-alone
LBPH
Healthcare
Crunching data... Almost there!
Dec'20Dec'21Dec'22Dec'23
Gross margin
0.0%
0.0%
0.0%
0.0%
LBPH
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for LBPH and see if it's the right time to invest.
Dive in

Longboard Pharmaceuticals, Inc. (LBPH) Gross margin comparison analysis

General

LTM Gross margin

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

Longboard Pharmaceuticals, Inc. logo
Longboard Pharmaceuticals, Inc.LBPH
50.0%
N/A
(4.8%)
N/A
Median Peer Set
84.1%
14.8%
(19.3%)
7.5%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
89.2%
23.6%
25.7%
41.5%
argenx SE logo
argenx SEARGX
86.8%
198.6%
(60.5%)
(24.1%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
86.1%
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
85.6%
23.0%
(38.6%)
(12.4%)
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
84.5%
8.3%
10.4%
31.1%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
83.7%
73.7%
467.1%
(35.9%)
BioNTech SE logo
BioNTech SEBNTX
80.3%
(77.4%)
(89.7%)
24.4%
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.BMRN
78.6%
18.0%
139.3%
15.0%
Royalty Pharma plc logo
Royalty Pharma plcRPRX
73.9%
(3.8%)
(43.7%)
37.9%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A

LBPH key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
Cost of Goods Sold (COGS)0.00.00.00.0
Gross Profit
% margin
0.0
0.0%
(0.0)
0.0%
(0.0)
0.0%
(0.0)
0.0%
Operating Expenses14.427.844.856.8
Research & Development Expenses (R&D)4.619.834.643.8
Selling, General & Administrative Expenses (SG&A)9.88.110.213.0
Operating Income
% margin
(14.4)
0.0%
(27.8)
0.0%
(44.8)
0.0%
(56.8)
0.0%
Interest Income0.00.10.82.4
Interest Expense0.00.00.80.0
Pre-tax Income(14.4)(27.8)(43.9)(54.4)
Income Tax
% effective tax rate
(0.0)
0.1%
(0.1)
0.2%
(0.9)
1.9%
0.0
0.0%
Net Income
% margin
(14.4)
0.0%
(27.7)
0.0%
(43.1)
0.0%
(54.4)
0.0%
EPS(0.82)(1.62)(2.51)(2.39)
Diluted EPS(0.82)(1.62)(2.51)(2.39)
EBITDA
% margin
(14.4)
0.0%
(27.8)
0.0%
(44.8)
0.0%
(56.8)
0.0%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Longboard Pharmaceuticals, Inc.'s Gross margin?

As of today, Microsoft Corp's last 12-month Gross margin is 50.0%, based on the financial report for Sep 30, 2024 (Q3’2024). The average annual Gross margin for Longboard Pharmaceuticals, Inc. have been 10.8% over the past three years, and 8.1% over the past five years.

2) Is Longboard Pharmaceuticals, Inc.'s Gross margin Good?

As of today, Longboard Pharmaceuticals, Inc.'s Gross margin is 50.0%, which is lower than industry median of 69.2%. It indicates that Longboard Pharmaceuticals, Inc.'s Gross margin is Bad.

3) How does Longboard Pharmaceuticals, Inc.'s Gross margin compare to its peers?

As of today, Longboard Pharmaceuticals, Inc.'s Gross margin is 50.0%, which is lower than peer median of 84.1%. The list of peers includes UTHR, ARGX, VRTX, ALNY, REGN, BGNE, BNTX, BMRN, RPRX, SMMT.